1
|
Rubnitz JE: Childhood acute myeloid
leukemia. Curr Treat Options Oncol. 9:95–105. 2008. View Article : Google Scholar
|
2
|
Byrd JC, Mrózek K, Dodge RK, Carroll AJ,
Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS,
et al; Cancer and Leukemia Group B (CALGB8461). Pretreatment
cytogenetic abnormalities are predictive of induction success,
cumulative incidence of relapse, and overall survival in adult
patients with de novo acute myeloid leukemia: results from Cancer
and Leukemia Group B (CALGB 8461). Blood. 100:4325–4336. 2002.
View Article : Google Scholar
|
3
|
Grimwade D, Walker H, Oliver F, Wheatley
K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A and
Goldstone A: The importance of diagnostic cytogenetics on outcome
in AML: analysis of 1,612 patients entered into the MRC AML 10
trial. The medical research council adult and children’s leukaemia
working parties. Blood. 92:2322–2333. 1998.PubMed/NCBI
|
4
|
Voutsadakis IA and Maillard N: Acute
myelogenous leukemia with the t(3;12)(q26;p13) translocation: case
report and review of the literature. Am J Hematol. 72:135–137.
2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Sitailo S, Sood R, Barton K and Nucifora
G: Forced expression of the leukemia-associated gene EVI1 in ES
cells: a model for myeloid leukemia with 3q26 rearrangements.
Leukemia. 13:1639–1645. 1999. View Article : Google Scholar : PubMed/NCBI
|
6
|
Mitelman F, Johansson B and Mertens F:
Mitelman database of chromosome aberrations and gene fusions in
cancer. 2013, http://cgap.nci.nih.gov/Chromosomes/Mitelman.
Accessed February 19, 2013
|
7
|
Raynaud SD, Baens M, Grosgeorge J, Rodgers
K, Reid CD, Dainton M, Dyer M, Fuzibet JG, Gratecos N, Taillan B,
et al: Fluorescence in situ hybridization analysis of
t(3;12)(q26;p13): a recurring chromosomal abnormality involving the
TEL gene (ETV6) in myelodysplastic syndromes. Blood. 88:682–689.
1996.
|
8
|
Fonatsch C, Gudat H, Lengfelder E, Wandt
H, Silling-Engelhardt G, Ludwig WD, Thiel E, Freund M, Bodenstein H
and Schwieder G: Correlation of cytogenetic findings with clinical
features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).
Leukemia. 8:1318–1326. 1994.
|
9
|
Mozziconacci MJ, Brunel V, Sainty D,
Amoulet C, Gabert J, Simonetti J and Lafage-Pochitaloff M:
Translocation (3,12)(q26.2;p13.1) in myeloid malignancies: a new
entity. Nouv Rev Fr Hematol. 37:481995.
|
10
|
Nishimura Y, Wada H, Mori A, Takatsuka H,
Tamura A, Fujimori Y, Okamoto T, Takemoto Y and Kakishita E:
Detection of ETV6/MDS1/Evi-1 chimeric transcripts in a patient with
acute myelocytic leukemia and t(3;12)(q26;p13). Int J Hematol.
72:108–109. 2000.PubMed/NCBI
|
11
|
Al-Achkar W, Wafa A and Nweder MS: A
complex translocation t(5;9;22) in Philadelphia cells involving the
short arm of chromosome 5 in a case of chronic myelogenous
leukemia. J Exp Clin Cancer Res. 26:411–415. 2007.
|
12
|
Shaffer L, Slovak M and Cambell L: ISCN
(2009): An International System for Human Cytogenetic Nomenclature.
Karger Publishers; Basel: pp. 15–33. 2009
|
13
|
Peeters P, Wlodarska I, Baens M, Criel A,
Selleslag D, Hagemeijer A, Van den Berghe H and Marynen P: Fusion
of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in
myeloproliferative disorders. Cancer Res. 57:564–569.
1997.PubMed/NCBI
|
14
|
Chen Z and Sandberg AA: Molecular
cytogenetic aspects of hematological malignacies: clinical
implications. Am J Med Genet. 115:130–141. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Byrd JC, Lawrence D, Arthur DC, et al:
Patients with isolated trisomy 8 in acute myeloid leukemia are not
cured with cytarabine-based chemotherapy: results from cancer and
leukemia group B 8461. Clin Cancer Res. 4:1235–1241. 1998.
|
16
|
Pedersen B: MDS and AML with trisomy 8 as
the sole chromosome aberration show different sex ratios and
prognostic profiles: a study of 115 published cases. Am J Hematol.
56:224–229. 1997. View Article : Google Scholar
|
17
|
Massaad L, Prieur M, Leonard C and
Dutrillaux B: Biclonal chromosome evolution of chronic
myelomonocytic leukemia in a child. Cancer Genet Cytogenet.
44:131–137. 1990. View Article : Google Scholar : PubMed/NCBI
|
18
|
Barjesteh van Waalwijk van
Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der
Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB,
Verhoef G, et al: High EVI1 expression predicts poor survival in
acute myeloid leukemia: a study of 319 de novo AML patients. Blood.
101:837–845. 2003.PubMed/NCBI
|
19
|
Ogawa S, Kurokawa M, Mitani K, Yazaki Y
and Hirai H: Overexpression of Evi-1 and dysmegakaryopoiesis in
human leukemias: reply to Carapeti, Goldman and Cross, Leukemia
1996; 10: 1561. Leukemia. 10:18491996.PubMed/NCBI
|
20
|
Iwase S, Furukawa Y, Horiguchi-Yamada J,
Nemoto T, Takahara S, Kawano T, Sekikawa T, Ito K, Yamazaki Y,
Kikuchi J, et al: A novel variant of acute myelomonocytic leukemia
carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome.
Int J Hematol. 67:361–368. 1998. View Article : Google Scholar
|
21
|
Fears S, Mathieu C, Zeleznik-Le N, Huang
S, Rowley JD and Nucifora G: Intergenic splicing of MDSI and EVIl
occurs in normal tissues as well as in myeloid leukemia and
produces a new member of the PR domain family. Proc Natl Acad Sci
USA. 93:1642–1647. 1996. View Article : Google Scholar
|